Nabla Bio
AI Healthcare
drug discovery / generative protein design
Series A
Nabla Bio is a Cambridge, Massachusetts–based biotechnology company focused on AI-driven generative protein design, using machine learning and wet-lab technologies to design antibodies and other protein therapeutics against hard-to-drug targets. The company collaborates with large pharmaceutical partners on therapeutics discovery and development, including AstraZeneca, Bristol Myers Squibb, and Takeda.
Company Details
- Website
- nabla.bio
- Headquarters
- Cambridge, Massachusetts, United States
- Founded
- 2020
- Funding
- $37M+ (reported); some sources indicate $107.38M total including later undisclosed rounds
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring